The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 17, 2026 for Espee Therapeutics LLP
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Espee Therapeutics LLP, part of the promoter group of Senores Pharmaceuticals Ltd, has created a pledge on 4,00,000 equity shares (0.87% of total share capital) of the company in favour of Bajaj Finance Limited. The pledge was created on February 13, 2026, and the reason stated is to secure a loan taken by Renosen Pharmaceuticals Private Limited (a related entity within the promoter group), making this a third-party pledge. Espee Therapeutics LLP holds 4,95,000 shares (1.07% of share capital) in total, so the pledge covers about 80% of its own holding in Senores. The disclosure has been filed under Regulation 31(1) and 31(2) of SEBI's SAST Regulations.
This is a relatively small pledge in terms of overall company share capital (under 1%), but it signals that a promoter group entity is using its Senores shares as collateral to raise funds for another group company. Investors should watch for any stress in Renosen Pharmaceuticals, as enforcement of this pledge by Bajaj Finance could lead to a change in shareholding of Senores Pharmaceuticals.